A5060471765- Mast cells and histamine
- Food Allergy and Anaphylaxis Research
- Ovarian cancer diagnosis and treatment
- Drug-Induced Adverse Reactions
- Chromatin Remodeling and Cancer
- Monoclonal and Polyclonal Antibodies Research
- Urticaria and Related Conditions
- Lymphoma Diagnosis and Treatment
Kings Health Partners
2022-2025
King's College London
2020-2025
Guy's Hospital
2022-2025
Abstract Background Survival rates for ovarian cancer remain poor, and monitoring prediction of therapeutic response may benefit from additional markers. Ovarian cancers frequently overexpress Folate Receptor alpha (FRα) the soluble receptor (sFRα) is measurable in blood. Here we investigated sFRα as a potential biomarker. Methods We evaluated longitudinally, before during neo-adjuvant, adjuvant palliative therapies, tumour FRα expression status by immunohistrochemistry. The impact free on...
IgE antibodies directed against cancer antigens have demonstrated potent anti-tumour effects in pre-clinical studies. MOv18 IgE, the first-in-class recognising antigen folate receptor alpha (FRα), showed preliminary signs of efficacy a Phase I trial. Treatment was well tolerated, with most common adverse event being transient urticarial skin reactions. We investigated immunological and allergic response parameters associated reactions IgE-treated patients. Expression target antigen, FRα,...
Abstract Background: All antibodies approved for the treatment of cancer are monoclonal IgGs, and no IgE therapy has yet been tested in humans. The biology IgE, compared with IgG, offers potential enhanced immune surveillance superior effector cell potency against tumor cells. preclinical models not associated allergic toxicity even immunocompetent animals, vivo efficacy compares favorably equivalent IgGs. Methods: We conducted a first-in-human first-in-class trial MOv18, chimeric patients...